Prevalence and incidence of anemia in thai patients with gynecologic cancer

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 5, 2010, Pages 1229-1233

  Achariyapota, Vuthinun ^a   Benjapibal, Mongkol ^a   Chaopotong, Pattama ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Anemia; Cancer; Frequency; Incidence; Prevalence

Indexed keywords

EID: 79956012830     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Aapro MS, Link H. (2008). September 2007 update on EORTC guidelines and anemia management with erythropoiesisstimulating agents. Oncologist, 13, 33-6.
2. Alici S, Kaya S, Izmirli M, et al. (2006). Analysis of survival factors in patients with adpvanced-stage gastric adenocarcinoma. Med Sci Monit, 12, CR221-9.
3. Barrett-Lee P, Bokemeyer C, Gascón P, et al. (2005). Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist, 10, 743-57.
4. Bron D, Meuleman N, Mascaux C. (2001). Biological basis of anemia. Semin Oncol, 28, 1-6.
5. Bokemeyer C, Aapro MS, Courdi A, et al. (2007). EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer, 43, 258-70.
6. Caro JJ, Salas M, Ward A, et al. (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 2214-21.
7. Cella D. (1998). Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol, 25, 43-6.
8. Demetri GD, Kris M, Wade J, et al. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol, 16, 3412-25.
9. Dicato M. (2003). Anemia in cancer: some pathophysiological aspects. Oncologist, 8, 19-21.
10. Dische S. (1991). Radiotherapy and anaemia--the clinical experience. Radiother Oncol, 20, 35-40.
11. Eisenhauer EA, Vermorken JB, van Glabbeke M. (1997). Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol, 8, 963-8.
12. Fucharoen S, Winichagoon P, Thonglairuam V. (1988). Betathalassemia associated with alpha-thalassemia in Thailand. Hemoglobin, 12, 581-92.
13. Glaspy J, Bukowski R, Steinberg D, et al. (1997). Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol, 15, 1218-34.
14. Hockel M, Schlenger K, Aral B, et al. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res, 56, 4509-15.
15. Knight K, Wade S, Balducci L. (2004). Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med, 116, 11S-26S.
16. Liang BC. (1996). Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol, 29, 149-55.
17. Ludwig H, Van Belle S, Barrett-Lee P, et al. (2004). The European Cancer Anaemia Survey. (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40, 2293-306.
18. Mercadante S, Gebbia V, Marrazzo A, et al. (2000). Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev, 26, 303-11.
19. Panich V, Pornpatkul M, Sriroongrueng W. (1992). The problem of thalassemia in Thailand. Southeast Asian J Trop Med Public Hlth, 23, 1-6.
20. Rizzo JD, Somerfield MR, Hagerty KL, et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol, 26, 132-49.
21. Seshadri T, Prince HM, Bell DR, et al. (2005). The Australian cancer anaemia survey: a snapshot of anaemia in adult patients with cancer. Med J Aust, 182, 453-7.
22. Tas F, Eralp Y, Basaran M, et al. (2002). Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol, 25, 371-9.
23. Thews O, Koenig R, Kelleher DK, et al. (1998). Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer, 78, 752-6.
24. Van Belle SJ, Cocquyt V. (2003). Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol, 47, 1-11.
25. Vaupel P, Thews O, Hoeckel M. (2001). Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol, 18, 243-59.
26. Vogelzang NJ, Breitbart W, Cella D, et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol, 34, 4-12.
27. Weiss G, Goodnough LT. (2005). Anemia of chronic disease. N Engl J Med, 352, 1011-23.